Kalamazoo, United States
Tetra Therapeutics, with its slogan "Restoring Clarity of Thought," is a United States-based clinical stage biotechnology company focusing on neurodegenerative and cognitive disorders. Founded in 2010, the company targets diseases such as Alzheimer's, Fragile X syndrome, Traumatic Brain Injury, major depression, and schizophrenia. Utilizing a novel approach targeting PDE4B and PDE4D, Tetra aims to enhance memory processing and cognitive function.
The company’s promising Alzheimer’s drug, BPN-14770, is under development in collaboration with the NIH Blueprint Therapeutics program. Tetra's PDE4B platform also addresses conditions like neuroinflammation, progressive multiple sclerosis, and chronic traumatic encephalopathy.
Tetra Therapeutics received a $5.00M Series A investment on 01 November 2016 with backing from Grand Angels and Apjohn Ventures. This investment reflects strong confidence in Tetra’s innovative therapeutic approach.
